Segment Information - Schedule of Reportable Segments (Details) - Reportable Subsegments [Member] - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Schedule of Reportable Segments [Line Items] | ||||
| Sales | $ 820,188 | $ 1,111,707 | $ 1,940,309 | $ 2,376,345 |
| Cost of sales | (635,994) | (650,813) | (1,352,956) | (1,422,038) |
| Research and development | (630,636) | (895,176) | (1,212,248) | (1,595,321) |
| General and Administrative | (1,621,095) | (1,718,774) | (3,153,110) | (3,211,735) |
| Amortization and depreciation | (53,201) | (53,202) | (106,403) | (107,781) |
| Foreign exchange gain (loss) | 18,136 | (47,753) | (38,858) | (28,443) |
| Interest and other income | 74,379 | 30,536 | 168,144 | 87,630 |
| Finance expense | (351,549) | (351,549) | ||
| Net Income (Loss) | (2,028,223) | (2,575,024) | (3,755,122) | (4,252,892) |
| Cash and Cash Equivalents | 6,954,834 | 5,583,039 | 6,954,834 | 5,583,039 |
| Pharma [Member] | ||||
| Schedule of Reportable Segments [Line Items] | ||||
| Sales | ||||
| Cost of sales | ||||
| Research and development | (624,644) | (890,513) | (1,200,102) | (1,582,352) |
| General and Administrative | (1,323,249) | (1,358,877) | (2,562,307) | (2,668,093) |
| Amortization and depreciation | (52,602) | (52,603) | (105,205) | (106,583) |
| Foreign exchange gain (loss) | 18,136 | (47,753) | (38,858) | (28,443) |
| Interest and other income | 74,379 | 30,536 | 168,144 | 87,630 |
| Finance expense | (351,549) | (351,549) | ||
| Net Income (Loss) | (1,907,980) | (2,670,759) | (3,738,328) | (4,649,390) |
| Cash and Cash Equivalents | 6,739,445 | 4,346,193 | 6,739,445 | 4,346,193 |
| Commercial [Member] | ||||
| Schedule of Reportable Segments [Line Items] | ||||
| Sales | 820,188 | 1,111,707 | 1,940,309 | 2,376,345 |
| Cost of sales | (635,994) | (650,813) | (1,352,956) | (1,422,038) |
| Research and development | (5,992) | (4,663) | (12,146) | (12,969) |
| General and Administrative | (297,846) | (359,897) | (590,803) | (543,642) |
| Amortization and depreciation | (599) | (599) | (1,198) | (1,198) |
| Foreign exchange gain (loss) | ||||
| Interest and other income | ||||
| Finance expense | ||||
| Net Income (Loss) | (120,243) | 95,735 | (16,794) | 396,498 |
| Cash and Cash Equivalents | $ 215,389 | $ 1,236,846 | $ 215,389 | $ 1,236,846 |
| X | ||||||||||
- Definition Represents the amount of interest and other income. No definition available.
|
| X | ||||||||||
- Definition Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of interest expense on finance lease liability. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|